within Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H02A_CorticosteroidsForSystemicUsePlain.H02AB12_Rimexolone;

model Rimexolone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 8.333333333333333e-08,
    adminDuration = 600,
    adminMass = 1 / 1000000,
    adminCount = 1,
    Vd = 0.003,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Rimexolone</td></tr><tr><td>ATC code:</td><td>H02AB12</td></tr><td>route:</td><td>topical</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>1</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.3</td><td>l/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Rimexolone is a synthetic glucocorticoid corticosteroid primarily formulated as ophthalmic suspension for topical use in the eye. It is used for the treatment of inflammation associated with ocular surgery and anterior uveitis, and to manage post-operative eye inflammation and pain. Approved for ophthalmologic use, it is currently available in some markets, though availability may be limited.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for topical ocular administration in adult humans, as limited or no human systemic PK data is available. Rimexolone displays very low systemic absorption when used as an ophthalmic suspension.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.H.H02AB12 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Rimexolone;
